Rectal Cancer: Who Fits the Dostarlimab Approval
FDA granted accelerated approval to dostarlimab for untreated stage II or III MSI-H or dMMR rectal cancer, highlighting early biomarker testing and potential organ preservation.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.